KR20150047510A - 미토콘드리아 관련 질환의 치료에서 사용하기 위한 알파-1-마이크로글로불린 - Google Patents
미토콘드리아 관련 질환의 치료에서 사용하기 위한 알파-1-마이크로글로불린 Download PDFInfo
- Publication number
- KR20150047510A KR20150047510A KR1020157005748A KR20157005748A KR20150047510A KR 20150047510 A KR20150047510 A KR 20150047510A KR 1020157005748 A KR1020157005748 A KR 1020157005748A KR 20157005748 A KR20157005748 A KR 20157005748A KR 20150047510 A KR20150047510 A KR 20150047510A
- Authority
- KR
- South Korea
- Prior art keywords
- deficiency
- mitochondrial
- microglobulin
- alpha
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201270538 | 2012-09-05 | ||
| DKPA201270538 | 2012-09-05 | ||
| DKPA201270557 | 2012-09-12 | ||
| DKPA201270557 | 2012-09-12 | ||
| PCT/EP2013/068270 WO2014037390A1 (en) | 2012-09-05 | 2013-09-04 | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150047510A true KR20150047510A (ko) | 2015-05-04 |
Family
ID=49162118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157005748A Ceased KR20150047510A (ko) | 2012-09-05 | 2013-09-04 | 미토콘드리아 관련 질환의 치료에서 사용하기 위한 알파-1-마이크로글로불린 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10226507B2 (enExample) |
| EP (1) | EP2900254B1 (enExample) |
| JP (2) | JP2015533790A (enExample) |
| KR (1) | KR20150047510A (enExample) |
| CN (1) | CN104661673A (enExample) |
| AU (1) | AU2013311714C1 (enExample) |
| BR (1) | BR112015003957A2 (enExample) |
| CA (1) | CA2881321A1 (enExample) |
| DK (1) | DK2900254T3 (enExample) |
| EA (1) | EA028963B1 (enExample) |
| ES (1) | ES2599034T3 (enExample) |
| HR (1) | HRP20161364T1 (enExample) |
| HU (1) | HUE030559T2 (enExample) |
| IN (1) | IN2015DN00515A (enExample) |
| MX (1) | MX357656B (enExample) |
| NZ (1) | NZ629621A (enExample) |
| PL (1) | PL2900254T3 (enExample) |
| PT (1) | PT2900254T (enExample) |
| SG (1) | SG11201500669SA (enExample) |
| WO (1) | WO2014037390A1 (enExample) |
| ZA (1) | ZA201500547B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016204360A (ja) * | 2015-02-25 | 2016-12-08 | エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ | 放射性核種療法における腎臓の保護に用いるためのアルファ−１−ミクログロブリン |
| KR20180116385A (ko) * | 2016-02-25 | 2018-10-24 | 에이원엠 파마 에이비 | 조영제의 사용과 관련하여 신장 보호에서 이용하기 위한 알파-1-마이크로글로불린 |
| ES2896734T3 (es) | 2016-03-18 | 2022-02-25 | Guard Therapeutics Int Ab | Proteínas novedosas derivadas de la alfa-1-microglobulina y su uso |
| GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
| CN109867717A (zh) * | 2019-04-01 | 2019-06-11 | 山西瑞亚力生物技术有限公司 | 一种血浆中α1微球蛋白的提取方法 |
| CN110452980B (zh) * | 2019-09-23 | 2023-07-28 | 武汉儿童医院 | 一种线粒体脑肌病诊断试剂盒及应用 |
| US20220362293A1 (en) * | 2019-09-25 | 2022-11-17 | Cytegen Corp. | Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products |
| CN115575646B (zh) * | 2022-11-21 | 2023-04-28 | 四川大学华西医院 | 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2547124A1 (en) * | 2003-11-26 | 2005-06-09 | Sanofi-Aventis Deutschland Gmbh | Tubular proteinuria as an indicator for elevated cardiovascular risk |
| MX347788B (es) * | 2007-02-12 | 2017-05-12 | A1M Pharma Ab | Diagnosis y tratamiento de preeclampsia. |
| EP2300614B1 (en) * | 2008-02-04 | 2015-10-28 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Methods and compositions for treatment of mitochondrial disorders |
| HUE027953T2 (en) * | 2008-07-18 | 2017-01-30 | A1M Pharma Ab | Medical use of the radical scavenger and antioxidant alpha-1 microglobulin |
-
2013
- 2013-09-04 MX MX2015002604A patent/MX357656B/es active IP Right Grant
- 2013-09-04 PL PL13759995T patent/PL2900254T3/pl unknown
- 2013-09-04 DK DK13759995.7T patent/DK2900254T3/en active
- 2013-09-04 HU HUE13759995A patent/HUE030559T2/en unknown
- 2013-09-04 EP EP13759995.7A patent/EP2900254B1/en not_active Not-in-force
- 2013-09-04 PT PT137599957T patent/PT2900254T/pt unknown
- 2013-09-04 KR KR1020157005748A patent/KR20150047510A/ko not_active Ceased
- 2013-09-04 US US14/423,260 patent/US10226507B2/en not_active Expired - Fee Related
- 2013-09-04 CN CN201380043567.0A patent/CN104661673A/zh active Pending
- 2013-09-04 HR HRP20161364TT patent/HRP20161364T1/hr unknown
- 2013-09-04 EA EA201590503A patent/EA028963B1/ru not_active IP Right Cessation
- 2013-09-04 CA CA2881321A patent/CA2881321A1/en not_active Abandoned
- 2013-09-04 WO PCT/EP2013/068270 patent/WO2014037390A1/en not_active Ceased
- 2013-09-04 IN IN515DEN2015 patent/IN2015DN00515A/en unknown
- 2013-09-04 SG SG11201500669SA patent/SG11201500669SA/en unknown
- 2013-09-04 AU AU2013311714A patent/AU2013311714C1/en not_active Ceased
- 2013-09-04 NZ NZ629621A patent/NZ629621A/en not_active IP Right Cessation
- 2013-09-04 BR BR112015003957A patent/BR112015003957A2/pt not_active Application Discontinuation
- 2013-09-04 ES ES13759995.7T patent/ES2599034T3/es active Active
- 2013-09-04 JP JP2015530375A patent/JP2015533790A/ja active Pending
-
2015
- 2015-01-23 ZA ZA2015/00547A patent/ZA201500547B/en unknown
-
2018
- 2018-08-24 JP JP2018157394A patent/JP2018203756A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10226507B2 (en) | 2019-03-12 |
| CN104661673A (zh) | 2015-05-27 |
| PL2900254T3 (pl) | 2017-02-28 |
| HRP20161364T1 (hr) | 2016-12-16 |
| AU2013311714B2 (en) | 2017-10-12 |
| ZA201500547B (en) | 2017-09-27 |
| MX357656B (es) | 2018-07-18 |
| IN2015DN00515A (enExample) | 2015-06-26 |
| SG11201500669SA (en) | 2015-02-27 |
| MX2015002604A (es) | 2015-06-10 |
| AU2013311714A1 (en) | 2015-03-12 |
| EP2900254A1 (en) | 2015-08-05 |
| JP2018203756A (ja) | 2018-12-27 |
| EA201590503A1 (ru) | 2015-06-30 |
| BR112015003957A2 (pt) | 2017-08-08 |
| NZ629621A (en) | 2015-09-25 |
| JP2015533790A (ja) | 2015-11-26 |
| EP2900254B1 (en) | 2016-08-03 |
| DK2900254T3 (en) | 2016-08-29 |
| HK1210585A1 (en) | 2016-04-29 |
| EA028963B1 (ru) | 2018-01-31 |
| ES2599034T3 (es) | 2017-01-31 |
| WO2014037390A1 (en) | 2014-03-13 |
| CA2881321A1 (en) | 2014-03-13 |
| US20150258171A1 (en) | 2015-09-17 |
| AU2013311714C1 (en) | 2018-01-25 |
| PT2900254T (pt) | 2016-10-18 |
| HUE030559T2 (en) | 2017-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20150047510A (ko) | 미토콘드리아 관련 질환의 치료에서 사용하기 위한 알파-1-마이크로글로불린 | |
| Liu et al. | Rhein attenuates cerebral ischemia-reperfusion injury via inhibition of ferroptosis through NRF2/SLC7A11/GPX4 pathway | |
| Ebeling et al. | Improving retinal mitochondrial function as a treatment for age-related macular degeneration | |
| Galloway et al. | Mitochondrial morphology—emerging role in bioenergetics | |
| Yin et al. | NDRG2 protects the brain from excitotoxicity by facilitating interstitial glutamate uptake | |
| Vigneswara et al. | Eye drop delivery of pigment epithelium-derived factor-34 promotes retinal ganglion cell neuroprotection and axon regeneration | |
| Wei et al. | Neuroglobin is an endogenous neuroprotectant for retinal ganglion cells against glaucomatous damage | |
| CN104023736A (zh) | Jnk信号转导途径的细胞-可渗透肽抑制剂用于治疗干眼综合征的用途 | |
| Lo et al. | Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2 | |
| Geng et al. | Mammalian STE20-like kinase 1 knockdown attenuates TNFα-mediated neurodegenerative disease by repressing the JNK pathway and mitochondrial stress | |
| JP2020536065A (ja) | 興奮性神経毒性に関連した損傷の治療用ペプチド組成物 | |
| KR102040893B1 (ko) | Arl6ip1의 유전성 강직성 하반신마비의 치료 용도 | |
| Yang et al. | Glial cells activation potentially contributes to the upregulation of stromal cell-derived factor-1α after optic nerve crush in rats | |
| HK1210585B (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases | |
| Li et al. | Protective effect of apelin-13 in lens epithelial cells via inhibiting oxidative stress-induced apoptosis | |
| Dal Cortivo et al. | Protein delivery to the eye: assessing therapeutic potential across inner and outer retina | |
| Wei et al. | Redefining cell death: ferroptosis as a game-changer in ophthalmology | |
| Vijayasarathy et al. | Organization and molecular interactions of retinoschisin in photoreceptors | |
| Jones | The role of optic atrophy 1 (OPA1) in the evolution of brain damage after neonatal hypoxic-ischaemic insult | |
| KR20240155868A (ko) | 외상성 뇌손상의 치료 방법 | |
| CN106999579A (zh) | 可辨识致病性tdp‑43的抗体及其用途 | |
| Matthiessen et al. | Loss of ciliary proteins IFT20 and IFT88 results in defective phagocytosis and metabolism in the RPE | |
| Alassaf | Pregnancy associated plasma protein-aa is a novel regulator of neuron survival | |
| Uggenti | Modification of mutant bestrophin-1 processing to prevent retinal degeneration | |
| Choudhury | Involvement of Caspase-7 in photoreceptor and retinal ganglion cell death |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |